Company Analysis

vTv Therapeutics Inc. (VTVT)

Nasdaq: VTVT · Pharmaceutical Preparations · High Point, NC · filing with the SEC since 2015
Grade5.3
◀ Past 3.4● Present 4.8▶ Future 6.9
5 est.

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedMar 10, 2026Mar 20, 2025Mar 13, 2024Mar 6, 2023Mar 29, 2022Feb 24, 2021Feb 21, 2020Feb 26, 2019Feb 27, 2018Feb 24, 2017
Revenue01,01702,0184,0056,4142,76412,434291634
For lenders
Interest and dividend income0010035200····
Interest and investment income1,8701,565472352112536111787
Interest expense on deposits and borrowings6013·······
Research and development17,86111,54613,59512,35713,32411,01515,11923,03539,64044,953
General and administrative14,94713,65111,90712,20112,3437,2518,5379,22311,3339,906
Total operating expenses32,80825,19725,50224,55825,66718,26623,65632,25850,97355,654
Operating income-32,808-24,180-25,502-22,540-21,662-11,852-20,892-19,824-50,682-55,020
Interest expense·01315126921,8273,2903,092398
Other income (expense), net··-1,497-3,6162,4480146·-22
Income before income taxes-31,080-22,605-25,966-24,873-17,616-12,802-21,838-23,645-53,847-55,353
Income tax expense0100020011501002008000
Net income including non-controlling interests-31,080-22,705-25,966-25,073-17,731-12,802-21,938-23,845-54,647-55,353
Net income to non-controlling interests-4,106-4,243-5,716-5,909-4,744-4,303-8,894-15,934-38,503-39,001
Net income-26,974-18,462-20,250-19,164-12,987-8,499-13,044-7,911-16,144-16,352
Net income to common shareholders-26,974-18,462-20,250-19,164-12,987-8,499-17,913-8,650-16,144-16,352
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:SalesRevenueNet
Interest and dividend income what its loans and securities earnedus-gaap:InterestIncomeOperating
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Interest expense on deposits and borrowings what it paid for the money it lendsus-gaap:InterestExpenseOperating
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
SI Assistanton VTVT · research, not advice